circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
=== Diagnostic tests === Once monoclonal antibodies for a given substance have been produced, they can be used to detect the presence of this substance. Proteins can be detected using the Western blot and immuno dot blot tests. In immunohistochemistry, monoclonal antibodies can be used to detect antigens in fixed tissue sections, and similarly, immunofluorescence can be used to detect a substance in either frozen tissue section or live cells.
=== Cavity-enhanced absorption spectrometry (CEAS) === The second way of improving the detectability of TDLAS technique is to extend the interaction length. This can be obtained by placing the species inside a cavity in which the light bounces back and forth many times, whereby the interaction length can be increased considerably. This has led to a group of techniques denoted as cavity enhanced AS (CEAS). The cavity can either be placed inside the laser, giving rise to intracavity AS, or outside, when it is referred to as an external cavity. Although the former technique can provide a high sensitivity, its practical applicability is limited because of all the non-linear processes involved. External cavities can either be of multi-pass type, i.e. Herriott or White cells, of non- resonant type (off-axis alignment), or of resonant type, most often working as a Fabry–Pérot (FP) etalon. Multi-pass cells, which typically can provide an enhanced interaction length of up to ~2 orders of magnitude, are nowaday common together with TDLAS. Resonant cavities can provide a much larger path length enhancement, in the order of the finesse of the cavity, F, which for a balanced cavity with high reflecting mirrors with reflectivities of ~99.99–99.999% can be ~ 104 to 105. It should be clear that if all this increase in interaction length can be utilized efficiently, this vouches for a significant increase in detectability.
A research study in which the medical records of groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke and those who do not smoke) are compared for a particular outcome. Also called a historic cohort study. (NCI) Retrospective study
Sources: en.wikipedia.org
1st Airborne Battle Group (ABG), 187th Infantry (reassigned from the 24th Infantry Division on 8 February 1959)(1) 1st ABG, 325th Infantry 2nd ABG, 501st Infantry 1st ABG, 503d Infantry (reassigned from the 24th Infantry Division on 1 July 1958)(2) 2nd ABG, 503rd Infantry (reassigned to the 25th Infantry Division on 24 June 1960) 1st ABG, 504th Infantry (reassigned to the 8th Infantry Division on 11 December 1958) 2nd ABG, 504th Infantry (assigned effective 9 May 1960)(1) 1st ABG, 505th Infantry (reassigned to the 8th Infantry Division on 15 January 1959) (1) 1st ABG, 504th Infantry and 1st ABG, 505th Infantry were reassigned to the 8th Infantry Division in central West Germany to provide airborne capability in Germany; in turn, 1–187th and 1-503d were reassigned from the 24th Infantry Division in southern Germany to the 82nd Airborne Division (2) 2nd ABG, 503rd Infantry was reassigned to the 25th Infantry Division and stationed in Okinawa to provide airborne capability in the Pacific on 24 June 1960. This ABG was reassigned to the 173d Airborne Brigade on 26 March 1963.
As the wood tiger moth has populations over a large range of latitudes, it has been observed that more northern populations showed higher rates of melanization. In both yellow and white male phenotypes of the wood tiger moth, individuals with more melanin had a heightened ability to trap heat but an increased predation rate due to a weaker and less effective aposematic signal. Melanin may protect Drosophila flies and mice against DNA damage from non-UV radiation.
The official name of the country, according to the constitution adopted concurrently with the UDI in November 1965, was Rhodesia, which derives from Cecil Rhodes. This was not the case under British law, however, which considered the territory's legal name to be Southern Rhodesia, the name given to the country in 1898 during the British South Africa Company's administration of the Rhodesias, and retained by the self-governing colony of Southern Rhodesia after the end of company rule in 1923. This naming dispute dated back to October 1964, when Northern Rhodesia became independent from the UK and concurrently changed its name to Zambia. The Southern Rhodesian colonial government in Salisbury felt that in the absence of a "Northern" Rhodesia, the continued use of "Southern" was superfluous. It passed legislation to become simply Rhodesia, but the British government refused to approve this on the grounds that the country's name was defined by British legislation, so could not be altered by the colonial government. Salisbury went on using the shortened name in an official manner nevertheless, while the British government continued referring to the country as Southern Rhodesia. This situation continued throughout the UDI period.
1. Canine cutaneous histiocytoma (derived from specialised epidermic dendritic cells, the Langerhans cells) 2. Reactive histiocytosis (immunohistochemical features show that interstitial/dermal DCs are involved) 2.a. Cutaneous histiocytosis (CH) 2.b. Systemic histiocytosis (SH) 3. Histiocytic sarcoma complex (immunohistochemical features of dendritic cells, possibly interdigitating or perivascular DCs) 3.a. Malignant histiocytosis 3.b. Histiocytic sarcoma Localized histiocytic sarcoma Diffuse histiocytic sarcoma
Sources: en.wikipedia.org
Due to the dynamic nature of O-GlcNAc and its presence on serine and threonine residues, O-GlcNAcylation is similar to protein phosphorylation in some respects. While there are roughly 500 kinases and 150 phosphatases that regulate protein phosphorylation in humans, there are only 2 enzymes that regulate the cycling of O-GlcNAc: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) catalyze the addition and removal of O-GlcNAc, respectively. OGT utilizes the sugar nucleotide UDP-GlcNAc as the donor sugar for transfer. First reported in 1984, this post-translational modification has since been identified on over 9,000 proteins in H. sapiens. Numerous functional roles for O-GlcNAcylation have been reported including crosstalking with serine/threonine phosphorylation, regulating protein-protein interactions, altering protein structure or enzyme activity, changing protein subcellular localization, and modulating protein stability and degradation. Numerous components of the cell's transcription machinery have been identified as being modified by O-GlcNAc, and many studies have reported links between O-GlcNAc, transcription, and epigenetics. Many other cellular processes are influenced by O-GlcNAc such as apoptosis, the cell cycle, and stress responses. As UDP-GlcNAc is the final product of the hexosamine biosynthetic pathway, which integrates amino acid, carbohydrate, fatty acid, and nucleotide metabolism, it has been suggested that O-GlcNAc acts as a "nutrient sensor" and responds to the cell's metabolic status.
In May 1950, after moving to Carter Products in New Jersey, Berger and a chemist, Bernard John Ludwig, synthesized a chemically related tranquilizing compound, meprobamate, that overcame these three drawbacks. Wallace Laboratories, a subsidiary of Carter Products, bought the license and named their new product "Miltown" after the borough of Milltown, New Jersey. Launched in 1955, it rapidly became the first blockbuster psychotropic drug in American history, becoming popular in Hollywood and gaining fame for its seemingly miraculous effects. It has since been marketed under more than 100 trade names, from Amepromat through Quivet to Zirpon. A December 1955 study of 101 patients at the Mississippi State Hospital in Whitfield, Rankin County, Mississippi, found meprobamate useful in the alleviation of "mental symptoms": 3% of patients made a complete recovery, 29% were greatly improved, 50% were somewhat better, while 18% realized little change. Self-destructive patients became cooperative and calmer, and experienced a resumption of logical thinking. In 50% of the cases, relaxation brought about more favorable sleep habits. Following the trial, hydrotherapy and all types of shock treatment were subsequently halted. Meprobamate was found to help in the treatment of alcoholics by 1956. By 1957, over 36 million prescriptions had been filled for meprobamate in the US alone, a billion pills had been manufactured, and it accounted for fully a third of all prescriptions written.
N-Desethyletonitazene (NDE, Noretonitazene) is a benzimidazole derivative with potent opioid effects which has been sold as a designer drug. It is better known as an active metabolite of the related compound etonitazene, but has similar activity to the parent compound and has sometimes appeared as a drug of abuse in its own right, first being identified in New Zealand in 2024.
which introduced the world's first umami seasoning: monosodium glutamate (MSG), marketed in Japan under the name "Ajinomoto." MSG subsequently spread worldwide as a seasoning capable of enhancing umami in a wide variety of dishes. In 2000, researchers at the University of Miami identified the presence of umami receptors on the tongue, and in 2006, Ajinomoto's research laboratories found similar receptors in the stomach.
Enewetak Atoll (; also spelled Eniwetok Atoll or sometimes Eniewetok; Marshallese: Ānewetak, [ænʲeːwɛːdˠɑk], or Āne-wātak, [ænʲeːwæːdˠɑk]; known to the Japanese as Brown Atoll or Brown Island; Japanese: ブラウン環礁) is a large coral atoll of 40 islands in the Pacific Ocean and with its 296 people (as of 2021) forms a legislative district of the Ralik Chain of the Marshall Islands. With a land area total less than 5.85 square kilometers (2.26 sq mi), it is no higher than 5 meters (16.4 ft) and surrounds a deep central lagoon, 80 kilometers (50 mi) in circumference. It is the second-westernmost atoll of the Ralik Chain and is 305 kilometers (190 mi) west from Bikini Atoll. It was held by the Japanese from 1914 until its capture by the United States in February 1944 during World War II, then became Naval Base Eniwetok. Nuclear testing by the US, totaling the equivalent of over 30 megatons of TNT, took place during the Cold War; in 1977–1980, a concrete dome (the Runit Dome) was built on Runit Island to deposit radioactive soil and debris. The Runit Dome is deteriorating and could be breached by a typhoon, though the sediments in the lagoon are even more radioactive than those which are contained.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.